{"id":"hydroxycarbamid","rwe":[],"tags":[],"safety":{"boxedWarnings":[],"safetySignals":[],"drugInteractions":[],"commonSideEffects":[],"contraindications":["Anemia","Breastfeeding (mother)","Kidney disease","Leukopenia","Postirradiation Erythema","Pregnancy, function","Severe Bone Marrow Depression","Thrombocytopenic disorder","Vasculitis of the skin"],"specialPopulations":{},"discontinuationRates":[],"seriousAdverseEvents":[]},"trials":[],"_chembl":null,"aliases":["siklos","Hydroxyurea"],"patents":[],"pricing":[],"offLabel":[],"timeline":[],"_dailymed":null,"ecosystem":[],"mechanism":{"target":"Carbonic anhydrase 2, Carbonic anhydrase 5A, mitochondrial, Carbonic anhydrase 9"},"_scrapedAt":"2026-03-28T02:22:57.971Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"references":[],"biosimilars":[],"competitors":[],"dataSources":[{"url":"https://drugcentral.org","name":"DrugCentral","fields":["indications","contraindications","safety","target","drugInteractions"],"retrievedDate":"2026-04-07"}],"indications":{"approved":[{"name":"Chronic myeloid leukemia","diseaseId":"chronic-myeloid-leukemia","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Hb SS disease","diseaseId":"hb-ss-disease","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Hemoglobin SS disease with crisis","diseaseId":"hemoglobin-ss-disease-with-crisis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Malignant melanoma","diseaseId":"malignant-melanoma","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Malignant tumor of head and/or neck","diseaseId":"malignant-tumor-of-head-and/or-neck","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Malignant tumor of ovary","diseaseId":"malignant-tumor-of-ovary","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Sickling disorder due to hemoglobin S","diseaseId":"sickling-disorder-due-to-hemoglobin-s","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"}],"offLabel":[],"pipeline":[]},"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT06456346","phase":"PHASE3","title":"Bomedemstat vs Hydroxyurea for Essential Thrombocythemia (MK-3543-007)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-07-16","conditions":"Essential Thrombocythemia","enrollment":300},{"nctId":"NCT06439082","phase":"PHASE3","title":"A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE)","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2024-10-24","conditions":"Sickle Cell Disease","enrollment":315},{"nctId":"NCT00920972","phase":"PHASE1, PHASE2","title":"Campath/Fludarabine/Melphalan Transplant Conditioning for Non-Malignant Diseases","status":"RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2001-12","conditions":"Metabolic Disorders, Hematologic, Immune, or Bone Marrow Disorders, Hemoglobinopathies","enrollment":220},{"nctId":"NCT06093672","phase":"PHASE3","title":"Study on Efficacy and Safety of Givinostat Versus Hydroxyurea in Patients With Polycythemia Vera","status":"RECRUITING","sponsor":"Italfarmaco","startDate":"2024-03-26","conditions":"Polycythemia Vera","enrollment":220},{"nctId":"NCT06871410","phase":"PHASE1","title":"Genetically Engineered Cells (CD83 CAR T Cells) for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia","status":"RECRUITING","sponsor":"Roswell Park Cancer Institute","startDate":"2026-03-02","conditions":"Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia","enrollment":26},{"nctId":"NCT06955169","phase":"PHASE2","title":"Comparing the Radiopharmaceutical Drug, [177Lu]Lu-DOTATATE, to Standard of Care Treatment for Patients With Meningioma That Has Come Back After Prior Treatment","status":"RECRUITING","sponsor":"RTOG Foundation, Inc.","startDate":"2025-12-24","conditions":"Intracranial Meningioma","enrollment":153},{"nctId":"NCT07488520","phase":"PHASE4","title":"Integrating Point of Care Testing (POCT) For Newborn Screening and Early Care for Sickle Cell Disease in Yopougon, Côte d'Ivoire","status":"NOT_YET_RECRUITING","sponsor":"Swiss Tropical & Public Health Institute","startDate":"2026-04","conditions":"Sickle Cell Disease (SCD)","enrollment":120},{"nctId":"NCT06079879","phase":"PHASE3","title":"A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2023-12-31","conditions":"Essential Thrombocythemia","enrollment":340},{"nctId":"NCT06930352","phase":"PHASE2","title":"Ziftomenib for the Treatment of Patients With NPM1 Mutated or KMT2A Rearranged Acute Myeloid Leukemia Not Eligible for Standard Therapy","status":"NOT_YET_RECRUITING","sponsor":"Uma Borate","startDate":"2026-04-10","conditions":"Acute Myeloid Leukemia","enrollment":70},{"nctId":"NCT05357482","phase":"PHASE1, PHASE2","title":"Addition of JSP191 (C-kit Antibody) to Nonmyeloablative Hematopoietic Cell Transplantation for Sickle Cell Disease and Beta-Thalassemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2022-05-12","conditions":"Sickle Cell Anemia, Beta Thalassemia","enrollment":40},{"nctId":"NCT05853458","phase":"PHASE4","title":"Evaluation of HU-resistance in Adult Patients With Polycythemia Vera Who Meet PV-AIM Predictors","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2023-07-28","conditions":"Polycythemia Vera","enrollment":76},{"nctId":"NCT06063317","phase":"PHASE1","title":"A Study of onCARlytics (CF33-CD19) in Combination With Blinatumomab in Adults With Advanced or Metastatic Solid Tumors (OASIS)","status":"TERMINATED","sponsor":"Imugene Limited","startDate":"2023-10-02","conditions":"Solid Tumor, Adult","enrollment":25},{"nctId":"NCT06526117","phase":"PHASE4","title":"Stroke Prevention in Nigeria 2 Trial","status":"RECRUITING","sponsor":"Vanderbilt University Medical Center","startDate":"2024-08-05","conditions":"Sickle Cell Disease, Stroke","enrollment":220},{"nctId":"NCT06923111","phase":"","title":"PASS of Xromi Comparing Safety and Effectiveness in Children Under 2 Years With Sickle Cell Disease [PRECISE PASS]","status":"RECRUITING","sponsor":"Nova Laboratories Limited","startDate":"2025-06-09","conditions":"Sickle Cell Disease","enrollment":180},{"nctId":"NCT07033598","phase":"PHASE2","title":"Pacritinib vs. Hydroxyurea in Advanced Proliferative Chronic Myelomonocytic Leukemia","status":"RECRUITING","sponsor":"Theradex","startDate":"2026-01-01","conditions":"Leukemia, Myelomonocytic, Chronic","enrollment":66},{"nctId":"NCT05526924","phase":"PHASE1","title":"Dosing Study of Radiation Combined With Tislelizumab and Pamiparib in Patients With Previously Treated Head and Neck Cancer","status":"RECRUITING","sponsor":"University of Chicago","startDate":"2023-03-07","conditions":"Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma, Head and Neck Carcinoma","enrollment":30},{"nctId":"NCT07232290","phase":"PHASE2","title":"Phase IIa Study on Flonoltinib Maleate Tablets in the Treatment of Patients With Polycythemia Vera","status":"RECRUITING","sponsor":"Chengdu Zenitar Biomedical Technology Co., Ltd","startDate":"2025-09-23","conditions":"Polycythemia Vera (PV)","enrollment":60},{"nctId":"NCT03165734","phase":"PHASE3","title":"A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis","status":"RECRUITING","sponsor":"Swedish Orphan Biovitrum","startDate":"2017-06-26","conditions":"Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis","enrollment":399},{"nctId":"NCT03974217","phase":"PHASE1","title":"Talazoparib for Cohesin-Mutated AML and MDS With Excess Blasts","status":"ACTIVE_NOT_RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2019-08-01","conditions":"Leukemia","enrollment":13},{"nctId":"NCT06979492","phase":"PHASE4","title":"Prophylactic Transfusion In Pregnant in Women With Sickle Cell Disease","status":"RECRUITING","sponsor":"Emory University","startDate":"2026-04","conditions":"Sickle Cell Disease, Pregnancy Related","enrollment":50},{"nctId":"NCT03511118","phase":"","title":"Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants","status":"RECRUITING","sponsor":"Duke University","startDate":"2018-10-04","conditions":"Lactating Women on Select DOI, Breastfed Infants of Mothers on Select DOI","enrollment":1600},{"nctId":"NCT03708731","phase":"","title":"Exploring Adherence Monitoring in Sickle Cell Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2019-03-12","conditions":"Sickle Cell Disease","enrollment":36},{"nctId":"NCT07116772","phase":"","title":"Serial Assessment of Fertility Experiences","status":"RECRUITING","sponsor":"Children's Hospital Medical Center, Cincinnati","startDate":"2023-07-10","conditions":"Sickle Cell Anemia","enrollment":250},{"nctId":"NCT03814746","phase":"PHASE3","title":"Study of Two Doses of Crizanlizumab Versus Placebo in Adolescent and Adult Sickle Cell Disease Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2019-07-26","conditions":"Sickle Cell Disease (SCD)","enrollment":255},{"nctId":"NCT06786234","phase":"PHASE1","title":"A Phase 1 Study to Assess STP938 as a Monotherapy in Adults With High Risk Essential Thrombocythaemia","status":"RECRUITING","sponsor":"Step Pharma, SAS","startDate":"2025-06-18","conditions":"Essential Thrombocythaemia","enrollment":20},{"nctId":"NCT04217356","phase":"","title":"Study of Stem Cell Transplant vs. Non-Transplant Therapies in High-Risk Myelofibrosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"University Health Network, Toronto","startDate":"2020-08-05","conditions":"Myelofibrosis, High-Risk Cancer, Bone Marrow Cancer","enrollment":90},{"nctId":"NCT03500731","phase":"PHASE1, PHASE2","title":"Lung and Bone Marrow Transplantation for Lung and Bone Marrow Failure","status":"RECRUITING","sponsor":"Paul Szabolcs","startDate":"2018-04-19","conditions":"Idiopathic Pulmonary Fibrosis, Emphysema or COPD","enrollment":8},{"nctId":"NCT04528355","phase":"","title":"Data Collection Study of Patients With Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT With RIC","status":"RECRUITING","sponsor":"Paul Szabolcs","startDate":"2020-08-20","conditions":"Primary Immunodeficiency (PID), Congenital Bone Marrow Failure Syndromes, Inherited Metabolic Disorders (IMD)","enrollment":50},{"nctId":"NCT05451940","phase":"PHASE1, PHASE2","title":"Hydroxyurea and EPO in Sickle Cell Disease","status":"COMPLETED","sponsor":"Julia Xu","startDate":"2023-05-25","conditions":"Anemia, Sickle Cell, Sickle Cell Disease","enrollment":17},{"nctId":"NCT03128996","phase":"PHASE1, PHASE2","title":"Reduced Intensity Conditioning and Familial HLA-Mismatched BMT for Non-Malignant Disorders","status":"RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2017-03-20","conditions":"Severe Sickle Cell Disease, Bone Marrow Failure Syndromes, Metabolic Disorders","enrollment":29},{"nctId":"NCT05405114","phase":"PHASE2","title":"Research Study Investigating How Well NDec Works in People With Sickle Cell Disease","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2022-07-07","conditions":"Sickle Cell Disease","enrollment":96},{"nctId":"NCT07292259","phase":"PHASE2","title":"Combination of Thalidomide and Hydroxyuria in Transfusion Dependent Thalasemmia","status":"RECRUITING","sponsor":"Pakistan Blood and Marrow Transplant (PBMT) Group","startDate":"2024-01-01","conditions":"Transfusion Dependent Beta Thalassemia","enrollment":150},{"nctId":"NCT05020652","phase":"PHASE2","title":"A Clinical Trial of TQ05105 Tablets in the Treatment of Moderate and High Risk Myelofibrosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2021-11-11","conditions":"Moderate and High Risk Myelofibrosis","enrollment":107},{"nctId":"NCT03013998","phase":"PHASE1, PHASE2","title":"Study of Biomarker-Based Treatment of Acute Myeloid Leukemia","status":"RECRUITING","sponsor":"Beat AML, LLC","startDate":"2016-11","conditions":"Previously Untreated Relapsed Refractory Acute Myeloid Leukemia","enrollment":3000},{"nctId":"NCT01962415","phase":"PHASE2","title":"Reduced Intensity Conditioning for Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT","status":"RECRUITING","sponsor":"Paul Szabolcs","startDate":"2014-02-04","conditions":"Primary Immunodeficiency (PID), Congenital Bone Marrow Failure Syndromes, Inherited Metabolic Disorders (IMD)","enrollment":100},{"nctId":"NCT04576156","phase":"PHASE3","title":"A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment","status":"ACTIVE_NOT_RECRUITING","sponsor":"Geron Corporation","startDate":"2021-04-12","conditions":"Myelofibrosis","enrollment":327},{"nctId":"NCT05398809","phase":"PHASE2","title":"Evaluate the Efficacy and Safety of Ruxolitinib on Hair Regrowth in Patients With Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy (APECED)-Associated Alopecia Areata","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2023-01-18","conditions":"Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy (Apeced), Alopecia Areata","enrollment":70},{"nctId":"NCT06552429","phase":"PHASE2","title":"Peginterferon α-2b Injection for Hydroxyurea Resistant or Intolerant ET","status":"RECRUITING","sponsor":"Xiamen Amoytop Biotech Co., Ltd.","startDate":"2024-08-29","conditions":"Essential Thrombocythemia","enrollment":27},{"nctId":"NCT05213572","phase":"","title":"Observational Study to Deeply Phenotype Major Organs in Sickle Cell Disease After Curative Therapies","status":"RECRUITING","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2022-03-24","conditions":"Mortality in Sickle Cell, Sickle Cell Cardiopulmonary Complications, Sickle Cell Organ Damage","enrollment":200},{"nctId":"NCT00726232","phase":"PHASE2","title":"Study to Determine the Safety and Efficacy of INCB018424 in Patients With Polycythemia Vera or Essential Thrombocythemia","status":"TERMINATED","sponsor":"Incyte Corporation","startDate":"2008-08-20","conditions":"Myeloproliferative Neoplasm (MPN)","enrollment":73},{"nctId":"NCT03474965","phase":"PHASE2","title":"Study of Dose Confirmation and Safety of Crizanlizumab in Pediatric Sickle Cell Disease Patients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2018-10-01","conditions":"Sickle Cell Disease (SCD)","enrollment":117},{"nctId":"NCT02158858","phase":"PHASE1, PHASE2","title":"A Phase 1/2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Hematologic and Myeloproliferative Malignancies","status":"COMPLETED","sponsor":"Constellation Pharmaceuticals","startDate":"2014-07-16","conditions":"Myelofibrosis, Leukemia, Myelocytic, Acute, Myelodysplastic/Myeloproliferative Neoplasm","enrollment":336},{"nctId":"NCT07210450","phase":"PHASE2, PHASE3","title":"Effect of L-Glutamine on Pulmonary Artery Pressure in Patients With Non-Transfusion-Dependent Thalassemia","status":"COMPLETED","sponsor":"Mazandaran University of Medical Sciences","startDate":"2023-08-15","conditions":"Pulmonary Artery Pressure, Thalassemia, Non-transfusion Dependent Thalassemia","enrollment":8},{"nctId":"NCT04562870","phase":"PHASE2","title":"A Study to Evaluate Single Agent Selinexor Versus Physician's Choice in Participants With Previously Treated Myelofibrosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Karyopharm Therapeutics Inc","startDate":"2021-03-17","conditions":"Myelofibrosis","enrollment":112},{"nctId":"NCT05249452","phase":"","title":"Adding Azathioprine/Hydroxyurea Preconditioning to Alemtuzumab/TBI to Reduce Risk of Graft Failure in MSD HSCT in Adult SCD Patients","status":"COMPLETED","sponsor":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","startDate":"2018-03-08","conditions":"Sickle Cell Disease","enrollment":20},{"nctId":"NCT04229979","phase":"PHASE3","title":"Galinpepimut-S Versus Investigator's Choice of Best Available Therapy for Maintenance in AML CR2/CRp2","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sellas Life Sciences Group","startDate":"2021-02-08","conditions":"Acute Myeloid Leukemia","enrollment":127},{"nctId":"NCT07170592","phase":"PHASE1","title":"A Phase 1 Study of OTS-412 (Recombinant Oncolytic Vaccinia Virus) in Treatment-refractory Solid Tumor Patients","status":"NOT_YET_RECRUITING","sponsor":"Bionoxx Inc.","startDate":"2025-12","conditions":"Treatment-Refractory Solid Tumors","enrollment":24},{"nctId":"NCT04662931","phase":"PHASE4","title":"An Indian Multi-centric Phase IV Study to Assess the Safety of Crizanlizumab in Sickle Cell Disease Patients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2021-07-14","conditions":"Sickle Cell Disease (SCD)","enrollment":140},{"nctId":"NCT07190833","phase":"PHASE1","title":"A Phase 1 Study of OTS-412 (Recombinant Oncolytic Vaccinia Virus) in Treatment-refractory Solid Tumor Patients (South Korea)","status":"NOT_YET_RECRUITING","sponsor":"Bionoxx Inc.","startDate":"2025-11","conditions":"Treatment-Refractory Solid Tumors","enrollment":27},{"nctId":"NCT05953584","phase":"PHASE2","title":"A Phase 2 Open-label Study to Evaluate the Activity of Etavopivat on Transcranial Doppler Velocities in Pediatric Patients With Sickle Cell Disease Who Are at Increased Risk for Primary Stroke","status":"RECRUITING","sponsor":"Forma Therapeutics, Inc.","startDate":"2023-06-20","conditions":"Sickle Cell Disease","enrollment":27},{"nctId":"NCT06578507","phase":"PHASE2","title":"Pharmacokinetics, Efficacy and Safety of Twice Daily Dosing Regimen of Hydroxycarbamide Dispersible Tablets in Children With Sickle Cell Disease","status":"RECRUITING","sponsor":"Theravia","startDate":"2025-01-21","conditions":"Sickle Cell Disease","enrollment":50},{"nctId":"NCT07177300","phase":"PHASE4","title":"Effectiveness of Nontraditional Hydroxyurea Algorithms: Novel and Clinical Evaluations (ENHANCE)","status":"RECRUITING","sponsor":"Children's Hospital Medical Center, Cincinnati","startDate":"2024-12-19","conditions":"Sickle Cell Anemia (HbSS), Sickle-β0-thalassemia (HbSβ0)","enrollment":50},{"nctId":"NCT06326190","phase":"PHASE2","title":"177Lu-DOTATATE for Recurrent Meningioma","status":"RECRUITING","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"2025-03-10","conditions":"Recurrent Meningioma","enrollment":136},{"nctId":"NCT03860844","phase":"PHASE2","title":"Isatuximab in Combination With Chemotherapy in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia","status":"TERMINATED","sponsor":"Sanofi","startDate":"2019-08-06","conditions":"Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia","enrollment":67},{"nctId":"NCT04808778","phase":"","title":"Stroke Prevention in Young Adults With Sickle Cell Anemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Vanderbilt University Medical Center","startDate":"2021-05-17","conditions":"Sickle Cell Disease, Sickle Cell Anemia, Stroke, Ischemic","enrollment":250},{"nctId":"NCT05548062","phase":"","title":"Study to Identify and Describe Predictive Factors for Thromboembolic Events in Patients With High-risk Polycythemia Vera","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2023-03-02","conditions":"Polycythemia Vera","enrollment":242},{"nctId":"NCT02769845","phase":"NA","title":"SACRED A Prospective Research Study to Reduce Stroke in Children With Sickle Cell Anemia","status":"COMPLETED","sponsor":"Children's Hospital Medical Center, Cincinnati","startDate":"2016-03-16","conditions":"Sickle Cell Anemia","enrollment":283},{"nctId":"NCT02556099","phase":"PHASE2","title":"EXTEND EXpanding Treatment for Existing Neurological Disease","status":"COMPLETED","sponsor":"Children's Hospital Medical Center, Cincinnati","startDate":"2014-08","conditions":"Sickle Cell Anemia","enrollment":43},{"nctId":"NCT04362293","phase":"PHASE2","title":"Reduced Intensity Transplantation for Severe Sickle Cell Disease","status":"SUSPENDED","sponsor":"St. Jude Children's Research Hospital","startDate":"2020-04-30","conditions":"Sickle Cell Disease","enrollment":40},{"nctId":"NCT04285086","phase":"PHASE3","title":"Ropeginterferon Alfa-2b (P1101) vs. Anagrelide in Essential Thrombocythemia Patients With Hydroxyurea Resistance or Intolerance","status":"ACTIVE_NOT_RECRUITING","sponsor":"PharmaEssentia","startDate":"2020-08-25","conditions":"Essential Thrombocythemia","enrollment":174},{"nctId":"NCT03653338","phase":"PHASE1, PHASE2","title":"T-Cell Depleted Alternative Donor Bone Marrow Transplant for Sickle Cell Disease (SCD) and Other Anemias","status":"RECRUITING","sponsor":"Paul Szabolcs","startDate":"2018-08-02","conditions":"Sickle Cell Anemia, Beta-thalassemia Major, Diamond-blackfan Anemia","enrollment":5},{"nctId":"NCT01461837","phase":"PHASE2","title":"Haplo T-Cell Depleted Transplantation in High-Risk Sickle Cell Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"New York Medical College","startDate":"2012-01","conditions":"Sickle Cell Disease","enrollment":21},{"nctId":"NCT05485948","phase":"PHASE2","title":"A Study to Access Efficacy and Safety of P1101 in Chinese PV Patients Who Are Intolerant or Resistance to HU","status":"ACTIVE_NOT_RECRUITING","sponsor":"PharmaEssentia","startDate":"2021-10-08","conditions":"Polycythemia Vera","enrollment":49},{"nctId":"NCT04093986","phase":"","title":"Hydroxyurea Exposure Limiting Pregnancy and Follow-Up Lactation","status":"RECRUITING","sponsor":"Children's Hospital Medical Center, Cincinnati","startDate":"2019-12-22","conditions":"Sickle Cell Disease, Sickle Cell Anemia","enrollment":200},{"nctId":"NCT03948867","phase":"PHASE2","title":"Stroke Prevention With Hydroxyurea Enabled Through Research and Education (SPHERE)","status":"ENROLLING_BY_INVITATION","sponsor":"Children's Hospital Medical Center, Cincinnati","startDate":"2019-04-24","conditions":"Sickle Cell Anemia in Children","enrollment":202},{"nctId":"NCT02286154","phase":"NA","title":"Therapeutic Response Evaluation and Adherence Trial (TREAT)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Hospital Medical Center, Cincinnati","startDate":"2014-10","conditions":"Anemia, Sickle Cell","enrollment":150},{"nctId":"NCT07066072","phase":"NA","title":"The Radiofrequency Therapy in Management of Sickle Cell Disease Chronic Pain RCT Tested the Effect of TECAR Therapy on Sickle Cell Disease Chronic Pain.","status":"COMPLETED","sponsor":"Cairo University","startDate":"2022-12-01","conditions":"the Use of Radiofrequency Ablation in Form of TECAR(Capacitive and Resistive Transfer Energy) in Chronic Pain of Sickle Cell Disease Patients","enrollment":170},{"nctId":"NCT06199557","phase":"PHASE1, PHASE2","title":"A Study to Investigate Treatment of HU and VPA, or 6-MP and VPA in Unfit AML/HR-MDS Patients","status":"RECRUITING","sponsor":"Haukeland University Hospital","startDate":"2024-05-23","conditions":"Acute Myeloid Leukemia, Adult, Myelodysplastic Syndromes, Adult","enrollment":48},{"nctId":"NCT03789591","phase":"PHASE3","title":"Hydroxyurea Optimization Through Precision Study","status":"COMPLETED","sponsor":"Lifespan","startDate":"2019-01-17","conditions":"Sickle Cell Disease, Sickle Cell Anemia","enrollment":104},{"nctId":"NCT03442114","phase":"NA","title":"Shared-Decision Making for Hydroxyurea","status":"COMPLETED","sponsor":"Children's Hospital Medical Center, Cincinnati","startDate":"2018-07-12","conditions":"Sickle Cell Anemia, Children, Only","enrollment":176},{"nctId":"NCT04687176","phase":"PHASE2","title":"Frontline Oral Arsenic Trioxide for APL","status":"RECRUITING","sponsor":"The University of Hong Kong","startDate":"2021-01-01","conditions":"Acute Promyelocytic Leukemia","enrollment":100},{"nctId":"NCT02577926","phase":"PHASE2","title":"The Ruxo-BEAT Trial in Patients With High-risk Polycythemia Vera or High-risk Essential Thrombocythemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"RWTH Aachen University","startDate":"2015-10","conditions":"Polycythemia Vera (PV), Essential Thrombocythemia (ET)","enrollment":207},{"nctId":"NCT06005324","phase":"PHASE1","title":"Personalized, Adaptive Treatment for Locally Advanced Head and Neck Cancer","status":"RECRUITING","sponsor":"University of Chicago","startDate":"2023-12-18","conditions":"HPV-Negative Squamous Cell Carcinoma","enrollment":36},{"nctId":"NCT06490601","phase":"PHASE2","title":"Long Term Beta Thalassemia Treatment: Findings From The Extension Period","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Institute of Blood and Marrow Transplant (NIBMT), Pakistan","startDate":"2022-04-01","conditions":"Fetal Hemoglobin, Beta-Thalassemia, Hemoglobinopathies","enrollment":30},{"nctId":"NCT02577406","phase":"PHASE3","title":"An Efficacy and Safety Study of AG-221 (CC-90007) Versus Conventional Care Regimens in Older Subjects With Late Stage Acute Myeloid Leukemia Harboring an Isocitrate Dehydrogenase 2 Mutation","status":"COMPLETED","sponsor":"Celgene","startDate":"2015-12-30","conditions":"Leukemia, Myeloid, Isocitrate Dehydrogenase","enrollment":319},{"nctId":"NCT06171217","phase":"PHASE2","title":"Realizing Effectiveness Across Continents With Hydroxyurea","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Hospital Medical Center, Cincinnati","startDate":"2023-10-27","conditions":"Sickle Cell Disease, Children","enrollment":810},{"nctId":"NCT03806452","phase":"PHASE2","title":"SIKAMIC (SIklos on Kidney Function and AlbuMInuria Clinical Trial)","status":"COMPLETED","sponsor":"Theravia","startDate":"2019-05-28","conditions":"Sickle Cell Disease","enrollment":86},{"nctId":"NCT01966731","phase":"PHASE1, PHASE2","title":"Realizing Effectiveness Across Continents With Hydroxyurea (REACH)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Hospital Medical Center, Cincinnati","startDate":"2014-06","conditions":"Sickle Cell Disease","enrollment":635},{"nctId":"NCT03944915","phase":"PHASE2","title":"De-Escalation Therapy for Human Papillomavirus Negative Disease","status":"COMPLETED","sponsor":"University of Chicago","startDate":"2019-08-26","conditions":"Human Papilloma Virus, Squamous Cell Carcinoma, Squamous Cell Carcinoma of the Head and Neck","enrollment":35},{"nctId":"NCT03107182","phase":"PHASE2","title":"Chemotherapy and Locoregional Therapy Trial (Surgery or Radiation) for Patients With Head and Neck Cancer","status":"COMPLETED","sponsor":"University of Chicago","startDate":"2017-06-27","conditions":"HPV-Related Squamous Cell Carcinoma, HNSCC","enrollment":72},{"nctId":"NCT04329325","phase":"PHASE2","title":"Blinatumomab and Tyrosine Kinase Inhibitor Therapy in People With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2020-03-30","conditions":"Acute Lymphoblastic Leukemia, Philadelphia Chromosome-Positive","enrollment":17},{"nctId":"NCT03263559","phase":"PHASE2","title":"Haploidentical Bone Marrow Transplantation in Sickle Cell Patients (BMTCTN1507)","status":"COMPLETED","sponsor":"Medical College of Wisconsin","startDate":"2017-10-03","conditions":"Sickle Cell Disease","enrollment":95},{"nctId":"NCT04750707","phase":"PHASE3","title":"Hydroxyurea Therapy for Neurological and Cognitive Protection in Pediatric Sickle Cell Anemia in Uganda ( BRAINSAFE-II )","status":"COMPLETED","sponsor":"Global Health Uganda LTD","startDate":"2021-03-09","conditions":"Sickle Cell Anemia in Children","enrollment":270},{"nctId":"NCT01499888","phase":"PHASE1, PHASE2","title":"Ph I/II Study of Allogeneic SCT for Clinically Aggressive Sickle Cell Disease (SCD)","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Illinois at Chicago","startDate":"2011-11-11","conditions":"Sickle Cell Disease","enrollment":45},{"nctId":"NCT05285917","phase":"PHASE3","title":"Promoting Utilization and Safety of Hydroxyurea Using Precision in Africa","status":"RECRUITING","sponsor":"Brown University","startDate":"2023-11-15","conditions":"Sickle Cell Anemia in Children, Sickle Cell Disease","enrollment":400},{"nctId":"NCT06264700","phase":"NA","title":"Applying Directly Observed Therapy to Hydroxyurea to Realize Effectiveness","status":"RECRUITING","sponsor":"Nationwide Children's Hospital","startDate":"2024-07-11","conditions":"Sickle Cell Disease","enrollment":60},{"nctId":"NCT06881056","phase":"NA","title":"Peginterferon α-2b Injection for Aerosol Therapy in Pediatric Respiratory Syncytial Virus Pneumonia","status":"RECRUITING","sponsor":"West China Second University Hospital","startDate":"2024-07-17","conditions":"Respiratory Syncytial Virus (RSV)","enrollment":90},{"nctId":"NCT01420783","phase":"PHASE2","title":"Study With SAR302503 in Patients With Polycythemia Vera or Essential Thrombocythemia","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2011-10","conditions":"Hematopoietic Neoplasm","enrollment":81},{"nctId":"NCT04126681","phase":"PHASE2","title":"A Pivotal Study of HQP1351 in Patients With Chronic Myeloid Leukemia in Chronic Phase","status":"COMPLETED","sponsor":"Ascentage Pharma Group Inc.","startDate":"2019-10-21","conditions":"Chronic Myeloid Leukemia, Chronic Phase","enrollment":144},{"nctId":"NCT04539678","phase":"","title":"SYTHROM Cohort, Myeloproliferative Neoplasia With Normal CBC and Thrombotic Complications","status":"COMPLETED","sponsor":"Nantes University Hospital","startDate":"2019-05-21","conditions":"Thrombotic Patients, Diagnosis of Myeloproliferative Neoplasia, Impact of Treatment With Cytoreducing Agent","enrollment":253},{"nctId":"NCT05662098","phase":"EARLY_PHASE1","title":"Alternative Dosing And Prevention of Transfusions (ADAPT)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Hospital Medical Center, Cincinnati","startDate":"2022-06-16","conditions":"Sickle Cell Disease","enrollment":100},{"nctId":"NCT06464458","phase":"NA","title":"Optimizing the Management of Sickle Cell Patients on Hydroxyurea: The Value of Therapeutic Pharmacological Monitoring","status":"RECRUITING","sponsor":"University Hospital, Strasbourg, France","startDate":"2023-02-08","conditions":"Sickle Cell Disease","enrollment":30},{"nctId":"NCT06318143","phase":"NA","title":"mAnaging siCkle CELl disEase Through incReased AdopTion of hydroxyurEa in Nigeria","status":"RECRUITING","sponsor":"New York University","startDate":"2024-07-01","conditions":"Sickle Cell Disease","enrollment":900},{"nctId":"NCT06761560","phase":"PHASE2, PHASE3","title":"Optimizing Hydroxyurea Dosage With Pharmakokinetic in Patients Suffering of Moderate to Severe Sickle Cell Anemia","status":"NOT_YET_RECRUITING","sponsor":"Yves Pastore","startDate":"2025-01-15","conditions":"Sickle Cell Disease (SCD)","enrollment":29},{"nctId":"NCT04691323","phase":"NA","title":"The Longitudinal Relationship of HU Adherence to HRQOL, Barriers to Adherence and Habit in SCD.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ann & Robert H Lurie Children's Hospital of Chicago","startDate":"2021-03-02","conditions":"Sickle Cell Disease, Sickle B+ Thalassemia, Sickle Beta Zero Thalassemia","enrollment":68},{"nctId":"NCT02165007","phase":"PHASE1","title":"Haploidentical Hematopoietic Stem Cell Transplantation","status":"COMPLETED","sponsor":"Catherine Bollard","startDate":"2015-01","conditions":"Sickle Cell-thalassemia Disease, Thalassemia","enrollment":7},{"nctId":"NCT06606886","phase":"PHASE4","title":"Effects of Hydroxyurea and Metformin in Transfusion Dependent Beta-Thalassemia","status":"RECRUITING","sponsor":"Bahria University","startDate":"2024-09-16","conditions":"Transfusion Dependent Beta-thalassemia","enrollment":96},{"nctId":"NCT04688411","phase":"NA","title":"An mHealth Strategy to Improve Medication Adherence in Adolescents With Sickle Cell Disease","status":"RECRUITING","sponsor":"Ann & Robert H Lurie Children's Hospital of Chicago","startDate":"2020-09-28","conditions":"Sickle Cell Disease, Sickle Beta Zero Thalassemia, Sickle B+ Thalassemia","enrollment":40},{"nctId":"NCT04116502","phase":"PHASE3","title":"MITHRIDATE: Ruxolitinib Versus Hydroxycarbamide or Interferon as First Line Therapy in High Risk Polycythemia Vera","status":"RECRUITING","sponsor":"University of Birmingham","startDate":"2019-10-25","conditions":"Polycythemia Vera","enrollment":586},{"nctId":"NCT03715972","phase":"","title":"Cerebrovascular Reserve and White Matter Disease in Patients with Chronic Anemia","status":"COMPLETED","sponsor":"Children's Hospital Los Angeles","startDate":"2018-07-15","conditions":"Thalassemia, Sickle Cell Disease, Healthy Controls","enrollment":165}],"_emaApprovals":[],"_faersSignals":[{"count":11,"reaction":"GENERAL PHYSICAL HEALTH DETERIORATION"},{"count":9,"reaction":"FATIGUE"},{"count":9,"reaction":"WEIGHT DECREASED"},{"count":5,"reaction":"ASTHENIA"},{"count":5,"reaction":"DECREASED APPETITE"},{"count":5,"reaction":"DYSPNOEA"},{"count":4,"reaction":"ANAEMIA"},{"count":4,"reaction":"DIARRHOEA"},{"count":4,"reaction":"DYSPHAGIA"},{"count":4,"reaction":"LEUKOCYTOSIS"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{},"formularyStatus":[],"_approvalHistory":[],"developmentCodes":[],"ownershipHistory":[],"publicationCount":5,"therapeuticAreas":["Oncology"],"biosimilarFilings":[],"companionDiagnostics":[],"genericManufacturerList":[],"phase":"phase_2","status":"active","brandName":"Hydroxycarbamid","genericName":"Hydroxycarbamid","companyName":"Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts","companyId":"centre-hospitalier-national-d-ophtalmologie-des-quinze-vingts","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Hydroxycarbamide, also known as hydroxyurea, is a small molecule inhibitor of the enzyme ribonucleoside-diphosphate reductase RR1. It has been studied in clinical trials for various conditions, including sickle cell anemia, myelofibrosis, leukemia, HIV infections, and sickle cell disease.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":17,"withResults":2},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}